Investor Presentaiton

Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars pelacarsen - ASO targeting Lp(a) NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Indication Cardiovascular risk reduction Phase Phase 3 Patients 8350 Primary Outcome Measures Arms Intervention Target Patients Time to the first occurrence of MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization) TQJ230 80 mg injected monthly subcutaneously or matched placebo Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically significant symptomatic Peripheral Artery Disease, and Lp(a) ≥ 70 mg/dL Read-out Milestone(s) 2025 Publication TBD 99 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation